论文部分内容阅读
在接受抗甲状腺药物(ATD)治疗的突眼性甲状腺肿615例患者中,215例(34.9％)发生毒性反应。包括颗粒细胞缺乏症1％,皮肤反应12.5％,白细胞减少6％,肝功能损害4.5％,水肿3.4％和胃肠反应2.9％。甲硫咪唑(MMI)引起毒性反应的发生率显著高于甲基疏氧嘧啶(MTU)(p<0.001)。本组患者的5年缓解率为56.2％,疗程1年的患者缓解率显著高于6个月者(p<0.05)。ATD复治患者的缓解率66.7％(12/18)。同时对ATD引起的颗粒细胞缺乏症和皮肤反应的处理以及影响复发的因素作了讨论。
Of the 615 patients with sudden goitre treated with antithyroid drugs (ATD), 215 (34.9%) developed toxic reactions. Including 1% of agranulocytosis, 12.5% of skin reactions, 6% of leukopenia, 4.5% of liver dysfunction, 3.4% of edema and 2.9% of gastrointestinal reactions. The incidence of toxicity induced by methimazole (MMI) was significantly higher than that of methylpoxolamine (p <0.001). The five-year remission rate was 56.2% in this group, and the remission rate was significantly higher in patients with one-year treatment than in six-month patients (p <0.05). The response rate of ATD retreatment patients was 66.7% (12/18). The treatment of ATD-induced agranulocytosis and skin reactions and the factors affecting recurrence are also discussed.